Teleflex INC 10-Q quarterly reports

Teleflex Incorporated's Q2 2026 Form 10-Q filing details strong revenue growth driven by the VI Business acquisition and strategic divestitures, alongside significant restructuring efforts.

Teleflex Incorporated reported a net loss for the first quarter of 2026, impacted by restructuring charges and strategic divestitures, despite an increase in net revenues driven by the BIOTRONIK VI Business acquisition.

Teleflex Incorporated reported a significant net loss of $408.9 million for the third quarter of 2025, primarily driven by a $403.9 million goodwill impairment charge related to its Interventional Urology North America unit and a $100 million asset impairment for the Titan SGS product line.

Teleflex Incorporated announced a significant increase in net income and EPS for the second quarter and year-to-date periods, driven by strategic cost management and favorable foreign currency hedging, despite mixed revenue performance and ongoing restructuring efforts.

Teleflex Incorporated's Q1 2025 results reveal a revenue decrease, strategic separation plans, and an acquisition to bolster its interventional product portfolio.

Teleflex's third-quarter results show a slight revenue increase but are impacted by restructuring costs and challenges in the UroLift market.

Teleflex Incorporated's second-quarter results show a slight revenue increase but are impacted by restructuring charges and market headwinds.

Teleflex's first quarter results show a net income of $15.3 million, impacted by a significant pension settlement charge, while revenue saw a modest increase.